NEW YORK (360Dx) – A team led by researchers at the German Cancer Research Center and Ruhr University Bochum has identified a blood-based marker that can identify patients likely to develop Alzheimer's disease more than a decade before the onset of symptoms.

The test measures the commonly used Alzheimer's protein biomarker amyloid-β (Aβ), but instead of measuring levels of different Aβ isoforms as is typically done, it looks for structural changes in Aβ indicative of the disease.